🚀 VC round data is live in beta, check it out!
Relmada Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Relmada Therapeutics and similar public comparables like Solid Biosciences, Oneness Biotech, MannKind, AprilBio and more.
Relmada Therapeutics Overview
About Relmada Therapeutics
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Founded
2012
HQ
Employees
17
Website
Sectors
Financials (LTM)
EV
$705M
Relmada Therapeutics Financials
Relmada Therapeutics reported last 12-month revenue of —.
In the same LTM period, Relmada Therapeutics generated had net loss of ($64M).
Revenue (LTM)
Relmada Therapeutics P&L
In the most recent fiscal year, Relmada Therapeutics reported revenue of — and EBITDA of ($59M).
Relmada Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($59M) | XXX | XXX | XXX |
| Net Profit | ($64M) | XXX | ($57M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Relmada Therapeutics Stock Performance
Relmada Therapeutics has current market cap of $798M, and enterprise value of $705M.
Market Cap Evolution
Relmada Therapeutics' stock price is $7.61.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $705M | $798M | 8.6% | XXX | XXX | XXX | $-0.55 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRelmada Therapeutics Valuation Multiples
Relmada Therapeutics trades at (11.9x) EV/EBITDA.
Relmada Therapeutics Financial Valuation Multiples
As of April 11, 2026, Relmada Therapeutics has market cap of $798M and EV of $705M.
Equity research analysts estimate Relmada Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Relmada Therapeutics has a P/E ratio of (12.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $798M | XXX | $798M | XXX | XXX | XXX |
| EV (current) | $705M | XXX | $705M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (11.9x) | XXX | XXX | XXX |
| EV/EBIT | (10.6x) | XXX | (11.9x) | XXX | XXX | XXX |
| P/E | (12.4x) | XXX | (13.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (15.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Relmada Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Relmada Therapeutics Margins & Growth Rates
Relmada Therapeutics' revenue in the last fiscal year grew by —.
Relmada Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $3.5M for the same period.
Relmada Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (30%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $3.5M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Relmada Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Solid Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Oneness Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| MannKind | XXX | XXX | XXX | XXX | XXX | XXX |
| AprilBio | XXX | XXX | XXX | XXX | XXX | XXX |
| Bioage Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Relmada Therapeutics M&A Activity
Relmada Therapeutics acquired XXX companies to date.
Last acquisition by Relmada Therapeutics was on XXXXXXXX, XXXXX. Relmada Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Relmada Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialRelmada Therapeutics Investment Activity
Relmada Therapeutics invested in XXX companies to date.
Relmada Therapeutics made its latest investment on XXXXXXXX, XXXXX. Relmada Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Relmada Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Relmada Therapeutics
| When was Relmada Therapeutics founded? | Relmada Therapeutics was founded in 2012. |
| Where is Relmada Therapeutics headquartered? | Relmada Therapeutics is headquartered in United States. |
| How many employees does Relmada Therapeutics have? | As of today, Relmada Therapeutics has over 17 employees. |
| Who is the CEO of Relmada Therapeutics? | Relmada Therapeutics' CEO is Sergio Traversa. |
| Is Relmada Therapeutics publicly listed? | Yes, Relmada Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Relmada Therapeutics? | Relmada Therapeutics trades under RLMD ticker. |
| When did Relmada Therapeutics go public? | Relmada Therapeutics went public in 2014. |
| Who are competitors of Relmada Therapeutics? | Relmada Therapeutics main competitors are Solid Biosciences, Oneness Biotech, MannKind, AprilBio. |
| What is the current market cap of Relmada Therapeutics? | Relmada Therapeutics' current market cap is $798M. |
| Is Relmada Therapeutics profitable? | No, Relmada Therapeutics is not profitable. |
| What is the current net income of Relmada Therapeutics? | Relmada Therapeutics' last 12 months net income is ($64M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.